Robbins LLP Urges PMI Stockholders to Contact the Firm for Information About the Class Action Against Picard Medical, Inc.

Core Viewpoint - A class action has been filed against Picard Medical, Inc. for alleged fraudulent activities related to stock promotion schemes, impacting investors who purchased shares between September 2, 2025, and October 31, 2025 [1][2]. Group 1: Allegations - The complaint alleges that Picard Medical was involved in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [2]. - It is claimed that insiders and affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The company's public statements and risk disclosures reportedly omitted critical information regarding false rumors and artificial trading activity that influenced the stock price [2]. Group 2: Stock Price Impact - On October 24, 2025, Picard Medical's stock price experienced a significant crash of 70%, dropping to $3.99 per share [3]. - Following the crash, the stock price has continued to decline, reaching approximately $2.00 per share [3]. Group 3: Shareholder Actions - Shareholders may be eligible to participate in the class action against Picard Medical, with a deadline to file as lead plaintiff by April 3, 2026 [4]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]. Group 4: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless a recovery is achieved [5]. - The firm has a history of advocating for shareholder rights and improving corporate governance since 2002 [5].